

Optic Neuropathy - Pipeline Review, H1 2020

<https://marketpublishers.com/r/OF593FB955FEN.html>

Date: February 2020

Pages: 70

Price: US\$ 2,000.00 (Single User License)

ID: OF593FB955FEN

Abstracts

Optic Neuropathy - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Optic Neuropathy - Pipeline Review, H1 2020, provides an overview of the Optic Neuropathy (Ophthalmology) pipeline landscape.

Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer treating drugs, stress related chemicals, some antibiotics and cyanogens.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Optic Neuropathy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Optic Neuropathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Optic Neuropathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 2, 3 and 2 respectively. Similarly, the

Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Optic Neuropathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Optic Neuropathy (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Optic Neuropathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Optic Neuropathy (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Optic Neuropathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline

projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Optic Neuropathy (Ophthalmology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Optic Neuropathy (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Optic Neuropathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Optic Neuropathy - Overview
- Optic Neuropathy - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Optic Neuropathy - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Optic Neuropathy - Companies Involved in Therapeutics Development
- Allergan Plc
- Antoxis Ltd
- Neurizon Pharma GBR
- Pharmatrophix Inc
- Quark Pharmaceuticals Inc
- Recursion Pharmaceuticals Inc
- Regenera Pharma Ltd
- Regeneron Pharmaceuticals Inc
- Optic Neuropathy - Drug Profiles
- afibercept - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- brimonidine tartrate implant - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- CSIC-002 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- ELN-41 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
Fab-3H4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-22A4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QPI-1007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPh-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Dominant Optic Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Neurological and Ophthalmological Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Connexin 43 for Optic Neuropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Optic Neuropathy - Dormant Projects
Optic Neuropathy - Discontinued Products
Optic Neuropathy - Product Development Milestones
Featured News & Press Releases
May 14, 2019: Regenera announces publication of RPh201 Phase 2a study data for the treatment of NAION in the Journal of Neuro-Ophthalmology
Oct 22, 2018: Quark Pharmaceuticals to present data on Optic Neuropathy drug candidate QPI-1007 at AAO 2018 Annual Meeting

Aug 06, 2018: Regenera Pharma enrolls first patient in Phase III trial of RPh201

Nov 13, 2017: RiboQuark Pharmaceutical Technology Announces Enrollment of The First Ever Patient in China for a Pivotal Clinical Trial with a siRNA Drug Candidate as Part of a Global Clinical Study of the Ocular Neuroprotectant QPI-1007

Oct 14, 2016: Quark Pharmaceuticals Launches EyeActNow.com to Promote NAION Study Steps-Up Recruitment for Phase II/III Research on 'Stroke of the Eye'

Sep 19, 2016: Quark Pharmaceuticals to provide an overview on siRNA candidate QPI-1007

Jul 29, 2016: Quark Pharmaceuticals Awarded Key Patent for QPI-1007 Ocular Neuroprotectant

Jun 23, 2016: Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India

Mar 14, 2016: Quark Pharmaceuticals Doses First Patient in Pivotal Phase III Study of RNAi-Based Therapeutic QPI-1007 for Eye Indications

Oct 27, 2015: Quark Pharmaceutical Announces Initiation of Patient Recruitment for Global Pivotal Study of QPI-1007 in NAION

Feb 28, 2014: Regenera Pharma has been initiated the Phase IIa study in patients with chronic Ischemic Optic Neuropathy

Apr 30, 2011: Regenera Pharma received the final report of its safety study in minipigs and is moving to human studies

Jun 24, 2010: Quark Pharmaceuticals Announces Presentation of its siRNA Drug Candidate QPI-1007 at Glaucoma & Retinopathies 2010

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Optic Neuropathy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Optic Neuropathy - Pipeline by Allergan Plc, H1 2020
Optic Neuropathy - Pipeline by Antoxis Ltd, H1 2020
Optic Neuropathy - Pipeline by Neurizon Pharma GBR, H1 2020
Optic Neuropathy - Pipeline by Pharmatrophix Inc, H1 2020
Optic Neuropathy - Pipeline by Quark Pharmaceuticals Inc, H1 2020
Optic Neuropathy - Pipeline by Recursion Pharmaceuticals Inc, H1 2020
Optic Neuropathy - Pipeline by Regenera Pharma Ltd, H1 2020
Optic Neuropathy - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
Optic Neuropathy - Dormant Projects, H1 2020
Optic Neuropathy - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Optic Neuropathy, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Allergan Plc

Antoxis Ltd

Neurizon Pharma GBR

Pharmatrophix Inc

Quark Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Regenera Pharma Ltd

Regeneron Pharmaceuticals Inc

I would like to order

Product name: Optic Neuropathy - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/OF593FB955FEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OF593FB955FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970